论文部分内容阅读
目的:评价培菲康联合思密达治疗小儿腹泻的临床疗效。方法:选取2013年5月至2015年4月该院收治的小儿腹泻患者93例,随机分为两组,其中观察组47例,选用培菲康联合思密达进行治疗,对照组46例,仅选用思密达进行治疗,观察并比较两组患儿的止泻时间以及临床有效率。结果:观察组患儿止泻时间以及临床有效率均明显优于对照组(P<0.05)。结论:培菲康联合思密达治疗小儿腹泻的临床疗效好,能在较短时间内发挥止泻作用,值得在临床上予以推广。
Objective: To evaluate the clinical efficacy of combination of pefloxacin and smecta in the treatment of infantile diarrhea. Methods: Ninety-three children with diarrhea admitted to our hospital from May 2013 to April 2015 were randomly divided into two groups (47 in observation group and 46 in control group) Only Smectite treatment was selected to observe and compare the two groups of children’s antidiarrheal time and clinical efficacy. Results: The antidiarrheal time and clinical effective rate in the observation group were significantly better than those in the control group (P <0.05). Conclusion: Pefikang combined with Smectite treatment of children with diarrhea, good clinical efficacy, can play a diarrhea in a relatively short period of time, it is worth to be promoted in the clinic.